Fatty liver promotes fibrosis in monkeys consuming high fructose

Cydylo, Michael A.; Davis, Ashley; Kavanagh, Kylie

doi:10.1002/oby.21720

Cited by 36 publications

(36 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one study in cynomolgus monkeys ( M. fascicularis ), the administration of fructose was shown to result in both an increase in liver fat and hepatic fibrosis after seven years, with the degree of fibrosis correlating with time of fructose exposure (42). Fructose-induced metabolic syndrome can also be induced in rhesus monkeys (43).…”

Section: Soft Drinks and Added Sugar Are Associated With Fatty Livermentioning

confidence: 99%

Fructose and sugar: A major mediator of non-alcoholic fatty liver disease

Jensen

Abdelmalek

Sullivan

et al. 2018

Journal of Hepatology

692

490

View full text Add to dashboard Cite

Nonalcoholic Fatty Liver Disease (NAFLD) is the hepatic manifestation of metabolic syndrome, and its rising prevalence parallels the rise in obesity and diabetes. Historically thought to result from overnutrition and sedentary lifestyle, recent evidence suggests that diets high in sugar (from sucrose and/or high fructose corn syrup (HFCS)) not only increases the risk for NAFLD, but also, nonalcoholic steatohepatitis (NASH). Here we review the experimental and clinical evidence that fructose precipitates fat accumulation in the liver, due to both increased lipogenesis and impaired fat oxidation. Recent evidence suggests that the predisposition to fatty liver is linked with metabolism of fructose by fructokinase C, resulting in ATP consumption, nucleotide turnover and uric acid generation that mediate fat accumulation. Alterations in gut permeability, microbiome, and associated endotoxemia contributes to the risk of NAFLD and NASH. Early clinical studies suggest that reducing sugary beverages and total fructose intake, especially from added sugars, may have a significant benefit on reducing hepatic fat accumulation. We suggest larger, more definitive trials to determine if lowering sugar/HFCS intake, and/or blocking uric acid generation, may help reduce NAFLD and its downstream complications of cirrhosis and chronic liver disease.

show abstract

Section: Soft Drinks and Added Sugar Are Associated With Fatty Livermentioning

confidence: 99%

Fructose and sugar: A major mediator of non-alcoholic fatty liver disease

Jensen

Abdelmalek

Sullivan

et al. 2018

Journal of Hepatology

692

490

View full text Add to dashboard Cite

show abstract

“…A very recent study 23 on 27 cynomolgus monkeys ( Macaca fascicularis ) over 7 years demonstrated that high-carbohydrate diets alone can generate both liver fat and fibrosis. The monkeys were fed diets with two diets: a control diet (CTL, n=10) or an HFr diet (n=17).…”

Section: Animal Studiesmentioning

confidence: 99%

Added fructose as a principal driver of non-alcoholic fatty liver disease: a public health crisis

2017

View full text Add to dashboard Cite

Fatty liver disease affects up to one out of every two adults in the western world. Data from animal and human studies implicate added sugars (eg, sucrose and high-fructose corn syrup) in the development of fatty liver disease and its consequences. Added fructose in particular, as a component of added sugars, may pose the greatest risk for fatty liver disease. Considering that there is no requirement for added sugars in the diet, dietary guidelines should recommend reducing the intake of added sugars to just 5% of total calories in order to decrease the prevalence of fatty liver disease and its related consequences.

show abstract

“…[89][90][91][92][93][94] Specifically, monkey predisposed to MetS (MetS-predisposed) could be an excellent model for NAFLD, which exhibits a higher body weight than healthy individual. [89][90][91][92][93][94] Specifically, monkey predisposed to MetS (MetS-predisposed) could be an excellent model for NAFLD, which exhibits a higher body weight than healthy individual.…”

Section: Other Animal Modelsmentioning

confidence: 99%

Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases

et al. 2018

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease which affects ≈25% of the adult population worldwide, placing a tremendous burden on human health. The disease spectrum ranges from simple steatosis to steatohepatitis, fibrosis, and ultimately, cirrhosis and carcinoma, which are becoming leading reasons for liver transplantation. NAFLD is a complex multifactorial disease involving myriad genetic, metabolic, and environmental factors; it is closely associated with insulin resistance, metabolic syndrome, obesity, diabetes, and many other diseases. Over the past few decades, countless studies focusing on the investigation of noninvasive diagnosis, pathogenesis, and therapeutics have revealed different aspects of the mechanism and progression of NAFLD. However, effective pharmaceuticals are still in development. Here, the current epidemiology, diagnosis, animal models, pathogenesis, and treatment strategies for NAFLD are comprehensively reviewed, emphasizing the outstanding breakthroughs in the above fields and promising medications in and beyond phase II.

show abstract

Fatty liver promotes fibrosis in monkeys consuming high fructose

Cited by 36 publications

References 19 publications

Fructose and sugar: A major mediator of non-alcoholic fatty liver disease

Fructose and sugar: A major mediator of non-alcoholic fatty liver disease

Added fructose as a principal driver of non-alcoholic fatty liver disease: a public health crisis

Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases

Contact Info

Product

Resources

About